A method for preparing ivosidenib and an intermediate thereof
WO2020247819A2
Methods of treatment with aminolevulinic acid synthase 2 (alas2) modulators
WO2020243376A1
Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020237047A1
Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
TW202045155A
Combination therapies for use in treating cancer
WO2020167976A1
Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
TW202039489A
Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
TW202039490A
Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
TW202039448A
Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
US2020085832A1
Deuterated analogs of an organic compound
AU2019299352A1
Ivosidenib forms and pharmaceutical compositions
US2019374522A1
Therapy for treating malignancies
KR20200138769A
Heterobicyclic inhibitors of Mat2A and methods of use thereof for cancer treatment
PH12019500368A1
Inhibitors of cellular metabolic processes
US2021113531A1
Methods of use for trisubstituted benzotriazole derivatives
EP3713919A1
Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
WO2019099651A1
Methods of using deuterated pyruvate kinase activators
WO2019099653A1
Therapeutically active compounds and their methods of use
WO2019090059A1
Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
